ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 1928 • ACR Convergence 2020

    Quantitative Ultrasound of Temporal, Axillary and Subclavian Arteries to Monitor Tocilizumab Treatment in Patients with Newly Diagnosed Giant Cell Arteritis: A 24 Week Analysis

    Luca Seitz1, Lisa Christ1, Godehard Scholz1, Fabian Lötscher1, Jennifer Amsler1, Florian Kollert1, Stephan Reichenbach1 and Peter Villiger1, 1Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland

    Background/Purpose: Tocilizumab (TCZ) suppresses CRP. Thus, CRP cannot be used as a marker for disease activity in GCA patients treated with TCZ and monitoring of…
  • Abstract Number: 0406 • ACR Convergence 2020

    Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients

    José Luis Martín-Varillas1, Belén Atienza-Mateo2, Vanesa Calvo-Río3, Emma Beltran-Catalan4, Alfredo Adan5, Marisa Hernandez Garfella6, Elia Valls-Pascual7, Agustín Sellas-Fernández8, N Ortego9, Alejandro Fonollosa10, Olga Maiz Alonso11, Ignacio Torre12, Cruz Fernández-Espartero13, Vega Jovani14, Diana Peiteado15, David Díaz Valle16, Susana Romero-Yuste17, Elena Aurrecoechea1, Miriam García-Arias18, Miguel Ángel Caracuel19, Santos Insúa20, Senén González-Suárez21, Amalia Sánchez Andrade22, Luis Francisco Linares23, Alfredo J García González24, Raquel Almodovar25, Carmen Carrasco Cubero26, María Alcalde Villar27, C Fernandez-Carballido28, Fred A Pages29, Eva Peña Sainz-Pardo24, Rosalia Demetrio-Pablo3, Santos Castañeda30, Miguel Ángel González-Gay31, José Luis Hernández3 and Ricardo Blanco3, 1Hospital Sierrallana, Torrelavega, Spain, 2Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Del Mar University Hospital, Barcelona, 5Hospital Clinic, Barcelona, Catalonia, Spain, 6H. Valencia, Valencia, Spain, 7H. Doctor Peset, Valencia, Spain, 8H. Vall d'Hebron, Barcelona, Spain, 9H. San Cecilio, Granada, Spain, 10H. de Cruces, Bilbao, Spain, 11Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 12Hospital Basurto, Bilbao, Spain, 13H. Mostoles, Madrid, Spain, 14H. Alicante, Alicante, Spain, 15Hospital La Paz - IdiPAZ, Madrid, Spain, 16H. Clínico San Carlos, Madrid, Spain, 17H Pontevedra, Coruna, Spain, 18H. La Princesa, Madrid, 19H.U. Reina Sofía, Córdoba, Spain, 20H. Santiago de Compostela, Santiago de Compostela, Spain, 21H. Cabueñes, Gijón, Spain, 22H. Lucus Augusti, Lugo, Spain, 23Hospital de la Arrixaca, Murcia, 24H. 12 de Octubre, Madrid, Spain, 25Fundación Alcorcón University Hospital, Madrid, 26H. Mérida, Mérida, Spain, 27H. Severo Ochoa, Madrid, Spain, 28H San Juan, Alicante, Spain, 29H. Palencia, Palencia, Spain, 30Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 31Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from…
  • Abstract Number: 0517 • ACR Convergence 2020

    Trends in the Incidence and Use of Diagnostic Modalities for Giant Cell Arteritis over Seven Decades: A Population-based Study

    Thomas Garvey1, Cynthia Crowson2, Matthew J. Koster3 and Kenneth Warrington3, 1Mayo Clinic Rochester, Apple Valley, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 3Mayo Clinic, Rochester, MN

    Background/Purpose: Diagnostic methods for giant cell arteritis (GCA) have evolved over recent decades, and large vessel imaging plays an increasing role in disease detection.   The…
  • Abstract Number: 1438 • ACR Convergence 2020

    Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)

    Jason Springer1 and Ryan Funk2, 1University of Kansas Medical Center, Overland Park, KS, 2UNIVERSITY OF KANSAS, Kansas City, KS

    Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…
  • Abstract Number: 1931 • ACR Convergence 2020

    Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis

    Naomi Serling-Boyd1, Xiaoqing Fu2, Yuqing Zhang3, Sebastian Unizony1, Zachary Wallace4, Hyon Choi5 and John H. Stone6, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
  • Abstract Number: 051 • 2020 Pediatric Rheumatology Symposium

    Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways

    Jessica Bloom1 and Robert Fuhlbrigge 2, 1Children's Hospital Colorado, Aurora, Colorado, 2University of Colorado, Aurora

    Background/Purpose: Immune-mediated diffuse alveolar hemorrhage (iDAH) is a life-threatening complication of pediatric rheumatologic diseases such as vasculitis, systemic lupus erythematosus, and antiphospholipid antibody syndrome. Delay…
  • Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium

    Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus

    Linda Wagner-Weiner 1, Vidya Sivaraman 2, Karen James 3, Eric Yen 4, Kathleen O'Neil 5, Dana Gerstbacher 6, Ann Marie Szymanski7, Kimberly Morishita 8 and David Cabral 9 for the CARRA investigators, 1University of Chicago, Chicago, Illinois, 2Division of Rheumatology, Nationwide Children's Hospital, Bexley, 3University of Utah, 84113, Utah, 4UCLA, Los Angeles, California, 5University of Indiana School of Medicine, Indianapolis, Indiana, 6Stanford University School of Medicine, Palo Alto, California, 7Tampa, Florida, 8University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, 9BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

    Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
  • Abstract Number: 084 • 2020 Pediatric Rheumatology Symposium

    Kawasaki Disease Shock Syndrome: A Single Center Cohort

    Monica Bray1, Jennifer Rammel 2, Andrea Ramirez 3, Kristen Sexson 4, Fong Lam 5, Eyal Muscal 1 and Marietta De Guzman 3, 1Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, 2Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 4Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, 5Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston

    Background/Purpose: Kawasaki disease (KD) is a well described vasculitis of childhood that is the leading cause of acquired heart disease in developed countries. Kawasaki disease…
  • Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium

    Implications of Positive Tests for ANCA in a Pediatric Population

    Karen James1, Peter Merkel 2 and Aimee Hersh 3, 1University of Utah, 84113, Utah, 2University of Pennsylvania, Philadelphia, 3University of Utah Primary Children's Hospital, Salt Lake City

    Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
  • Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium

    Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

    Simone Melega 1, Paul Brogan2, Gavin Cleary 3, Aimee Hersh 4, Ozgur Kasapcopur 5, Satyapal Rangaraj 6, Rae Yeung 7, Andrew Zeft 8, Jennifer Cooper 9, Pooneh Pordeli 10, Petra Kirchner 11 and Patricia Lehane 12, 1F. Hoffmann-La Roche, Ltd., Basel, Switzerland, 2UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 3Alder Hey Children's Hospital, Liverpool, United Kingdom, 4University of Utah Primary Children's Hospital, Salt Lake City, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, 6Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, 7The Hospital for Sick Children, Toronto, Canada, 8The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, 9University of Colorado, Children's Hospital Colorado, Denver, 10F. Hoffmann-La Roche, Ltd., Mississauga, Canada, 11F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, 12Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
  • Abstract Number: 871 • 2019 ACR/ARP Annual Meeting

    ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry

    Zachary Wallace1, Huifeng Yun 2, Jeffrey Curtis 2, Shuo Yang 2, Lang Chen 2, John Stone 3 and Hyon K. Choi 4, 1Massachusetts General Hospital, Boston, 2University of Alabama at Birmingham, Birmingham, AL, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens.  As such, treatment…
  • Abstract Number: 1688 • 2019 ACR/ARP Annual Meeting

    Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial

    Benjamin Terrier1, Jonathan London 2, Fabrice Bonnet 3, Diane Cerutti 4, Nathalie Costedoat-Chalumeau 5, Elisabeth Diot 6, Yasmina Ferfar 7, Aurélie Hummel 8, Gilles Kaplanski 9, Isabelle Marie 10, Thomas Quémeneur 11, Patricia Rullier 12, Patricia Senet 13, Noémie Le Gouellec 14, Julie Lejeune 7, David Saadoun 15 and Patrice Cacoub 15, 1National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, 2Croix Saint-Simon Hospital, Paris, France, 3CHU, Bordeaux, France, 4CH, Toulon, France, 5Cochin University Hospital, Paris, France, 6APHP, Tours, France, 7Pitié-Salpétrière Hospital, Paris, France, 8APHP, Paris, France, 9CHU, Marseille, France, 10CHU, Rouen, France, 11CH Valenciennes, Valenciennes, France, 12CHU, Montpellier, France, 13Tenon Hospital, Paris, France, 14CH, Valenciennes, France, 15AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

    Background/Purpose: A previous retrospective study suggested superiority of glucocorticoids (GCs) plus rituximab (RTX) compared to GCs alone to induce complete clinical response in non-infectious cryoglobulinemia…
  • Abstract Number: 2635 • 2019 ACR/ARP Annual Meeting

    Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Tanaz Kermani1, Jason Springer 2, Antoine Sreih 3, Dianne Shaw 4, Kalen Young 5, Cristina Burroughs 6 and Peter Merkel 3, 1University of California Los Angeles, Los Angeles, CA, 2Kansas University Medical Center, Kansas, MO, 3University of Pennsylvania, Philadelphia, PA, 4Vasculitis Foundation, North Carolina, 5Vasculitis Foundation, Kansas City, MO, 6University of South Florida, Tampa, FL

    Background/Purpose: To determine the reliability of self-reported diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with…
  • Abstract Number: 873 • 2019 ACR/ARP Annual Meeting

    Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database

    Sebastian E. Sattui1, Zafir Abutalib 2, Jackie Finik 2 and Robert Spiera 3, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY, New York, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Pulmonary involvement, including pulmonary vascular disease and interstitial lung disease can be an important cause of morbidity and even mortality in patients with primary…
  • Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting

    Efficacy of Leflunomide for Treatment of Vasculitis

    NOURA MUSTAPHA 1, Lillian Barra 2, Simon Carette 3, David Cuthbertson 4, Nader A. Khalidi 5, Curry L. Koening 6, Carol Langford 7, Carol McAlear 8, Nataliya Milman 9, Larry Moreland 10, Paul Monach 11, Philip Seo 12, Ulrich Specks 13, Antoine Sreih 14, Steven Ytterberg 13, Peter Merkel 14, Christian Pagnoux15, CanVasc Canadian Vasculitis Research Network 16 and VCRC Vasculitis Clinical Research Consortium 8, 1Hopital Notre Dame, Montreal, QC, Canada, 2St Joseph's health care, London, Canada, 3Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6University of Utah Hospital, Salt Lake City, UT, 7Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Division of Rheumatology, Philadelphia, 9Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, 10University of Pittsburgh, PITTSBURGH, PA, 11Brigham and Women's Hospital, Boston, MA, 12Johns Hopkins Medicine, Baltimore, MD, 13Mayo Clinic College of Medicine, Rochester, MN, 14University of Pennsylvania, Philadelphia, PA, 15Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 16Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada

    Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology